Comprehensively understanding fatigue in patients with myeloproliferative neoplasms

Robyn M. Scherber; Heidi E. Kosiorek; Zhenya Senyak; Amylou C. Dueck; Matthew M. Clark; Michael A. Boxer; Holly L. Geyer; Archie McCallister; Mary Cotter; Barbara Van Husen; Claire N. Harrison; Ruben A. Mesa

doi:10.1002/cncr.29753

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms

Robyn M. Scherber, Heidi E. Kosiorek, Zhenya Senyak, Amylou C. Dueck, Matthew M. Clark, Michael A. Boxer, Holly L. Geyer, Archie McCallister, Mary Cotter, Barbara Van Husen, Claire N. Harrison, Ruben A. Mesa

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Abstract

BACKGROUND Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs. METHODS A 70-item, Internet-based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center. RESULTS Fatigue was found to be prevalent and severe among international survey respondents (1788 respondents). Higher body mass index (P<.001), current use of alcohol (P<.001), and current tobacco use (P = .0025) were found to be significantly associated with greater fatigue. Moderate/severe fatigue was present more frequently in those individuals who did not exercise compared with those who reported exercising at least once per week (P<.001). Medical comorbidities found to be significantly associated with greater fatigue included restless leg syndrome (P = .006), diabetes mellitus (P = .045), fibromyalgia (P < 0.001), chronic fatigue syndrome (P = .006), and chronic kidney disease (P = .02). Current use of antidepressants (P<.001), antihistamines (P = .0276), antianxiety medications (P = .0357), and prescription pain medications (P<.001) were found to be associated with worsened fatigue. Nearly 25% of respondents scored > 2 on the Patient Health Questionnaire, indicating a high probability of depression. Higher Brief Fatigue Inventory score, Myeloproliferative Neoplasm Total Symptom Score, and individual symptom items were all associated with a higher likelihood of depressive symptoms (P<.0001). CONCLUSIONS The management of fatigue should be multifactorial, with a comprehensive assessment and treatment plan to address all modifiable fatigue etiologies. Patients with MPNs likely have a higher prevalence of mood disturbances compared with the general population, suggesting the need to assess and intervene in this domain. Cancer 2016;122:477-485.

Original language	English (US)
Pages (from-to)	477-485
Number of pages	9
Journal	Cancer
Volume	122
Issue number	3
DOIs	https://doi.org/10.1002/cncr.29753
State	Published - Feb 1 2016
Externally published	Yes

Keywords

essential thrombocythemia
fatigue
myelofibrosis
polycythemia vera
quality of life

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.29753

Cite this

@article{70fb0e690c4e41d483e274ca1531a0a8,

title = "Comprehensively understanding fatigue in patients with myeloproliferative neoplasms",

abstract = "BACKGROUND Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs. METHODS A 70-item, Internet-based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center. RESULTS Fatigue was found to be prevalent and severe among international survey respondents (1788 respondents). Higher body mass index (P<.001), current use of alcohol (P<.001), and current tobacco use (P = .0025) were found to be significantly associated with greater fatigue. Moderate/severe fatigue was present more frequently in those individuals who did not exercise compared with those who reported exercising at least once per week (P<.001). Medical comorbidities found to be significantly associated with greater fatigue included restless leg syndrome (P = .006), diabetes mellitus (P = .045), fibromyalgia (P < 0.001), chronic fatigue syndrome (P = .006), and chronic kidney disease (P = .02). Current use of antidepressants (P<.001), antihistamines (P = .0276), antianxiety medications (P = .0357), and prescription pain medications (P<.001) were found to be associated with worsened fatigue. Nearly 25% of respondents scored > 2 on the Patient Health Questionnaire, indicating a high probability of depression. Higher Brief Fatigue Inventory score, Myeloproliferative Neoplasm Total Symptom Score, and individual symptom items were all associated with a higher likelihood of depressive symptoms (P<.0001). CONCLUSIONS The management of fatigue should be multifactorial, with a comprehensive assessment and treatment plan to address all modifiable fatigue etiologies. Patients with MPNs likely have a higher prevalence of mood disturbances compared with the general population, suggesting the need to assess and intervene in this domain. Cancer 2016;122:477-485.",

keywords = "essential thrombocythemia, fatigue, myelofibrosis, polycythemia vera, quality of life",

author = "Scherber, {Robyn M.} and Kosiorek, {Heidi E.} and Zhenya Senyak and Dueck, {Amylou C.} and Clark, {Matthew M.} and Boxer, {Michael A.} and Geyer, {Holly L.} and Archie McCallister and Mary Cotter and {Van Husen}, Barbara and Harrison, {Claire N.} and Mesa, {Ruben A.}",

note = "Publisher Copyright: {\textcopyright} 2015 American Cancer Society.",

year = "2016",

month = feb,

day = "1",

doi = "10.1002/cncr.29753",

language = "English (US)",

volume = "122",

pages = "477--485",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "3",

}

TY - JOUR

T1 - Comprehensively understanding fatigue in patients with myeloproliferative neoplasms

AU - Scherber, Robyn M.

AU - Kosiorek, Heidi E.

AU - Senyak, Zhenya

AU - Dueck, Amylou C.

AU - Clark, Matthew M.

AU - Boxer, Michael A.

AU - Geyer, Holly L.

AU - McCallister, Archie

AU - Cotter, Mary

AU - Van Husen, Barbara

AU - Harrison, Claire N.

AU - Mesa, Ruben A.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - BACKGROUND Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs. METHODS A 70-item, Internet-based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center. RESULTS Fatigue was found to be prevalent and severe among international survey respondents (1788 respondents). Higher body mass index (P<.001), current use of alcohol (P<.001), and current tobacco use (P = .0025) were found to be significantly associated with greater fatigue. Moderate/severe fatigue was present more frequently in those individuals who did not exercise compared with those who reported exercising at least once per week (P<.001). Medical comorbidities found to be significantly associated with greater fatigue included restless leg syndrome (P = .006), diabetes mellitus (P = .045), fibromyalgia (P < 0.001), chronic fatigue syndrome (P = .006), and chronic kidney disease (P = .02). Current use of antidepressants (P<.001), antihistamines (P = .0276), antianxiety medications (P = .0357), and prescription pain medications (P<.001) were found to be associated with worsened fatigue. Nearly 25% of respondents scored > 2 on the Patient Health Questionnaire, indicating a high probability of depression. Higher Brief Fatigue Inventory score, Myeloproliferative Neoplasm Total Symptom Score, and individual symptom items were all associated with a higher likelihood of depressive symptoms (P<.0001). CONCLUSIONS The management of fatigue should be multifactorial, with a comprehensive assessment and treatment plan to address all modifiable fatigue etiologies. Patients with MPNs likely have a higher prevalence of mood disturbances compared with the general population, suggesting the need to assess and intervene in this domain. Cancer 2016;122:477-485.

AB - BACKGROUND Patients with myeloproliferative neoplasms (MPNs) experience a high persistence, prevalence, and severity of fatigue. There is currently only limited information regarding factors that contribute to fatigue in patients with MPNs. METHODS A 70-item, Internet-based survey regarding fatigue was developed by MPN investigators and patients/advocates and hosted by the Mayo Clinic Survey Research Center. RESULTS Fatigue was found to be prevalent and severe among international survey respondents (1788 respondents). Higher body mass index (P<.001), current use of alcohol (P<.001), and current tobacco use (P = .0025) were found to be significantly associated with greater fatigue. Moderate/severe fatigue was present more frequently in those individuals who did not exercise compared with those who reported exercising at least once per week (P<.001). Medical comorbidities found to be significantly associated with greater fatigue included restless leg syndrome (P = .006), diabetes mellitus (P = .045), fibromyalgia (P < 0.001), chronic fatigue syndrome (P = .006), and chronic kidney disease (P = .02). Current use of antidepressants (P<.001), antihistamines (P = .0276), antianxiety medications (P = .0357), and prescription pain medications (P<.001) were found to be associated with worsened fatigue. Nearly 25% of respondents scored > 2 on the Patient Health Questionnaire, indicating a high probability of depression. Higher Brief Fatigue Inventory score, Myeloproliferative Neoplasm Total Symptom Score, and individual symptom items were all associated with a higher likelihood of depressive symptoms (P<.0001). CONCLUSIONS The management of fatigue should be multifactorial, with a comprehensive assessment and treatment plan to address all modifiable fatigue etiologies. Patients with MPNs likely have a higher prevalence of mood disturbances compared with the general population, suggesting the need to assess and intervene in this domain. Cancer 2016;122:477-485.

KW - essential thrombocythemia

KW - fatigue

KW - myelofibrosis

KW - polycythemia vera

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=84950335752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950335752&partnerID=8YFLogxK

U2 - 10.1002/cncr.29753

DO - 10.1002/cncr.29753

M3 - Article

C2 - 26670597

AN - SCOPUS:84950335752

SN - 0008-543X

VL - 122

SP - 477

EP - 485

JO - Cancer

JF - Cancer

IS - 3

ER -

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this